 SYDNEY, AUSTRALIA, June 04, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from its Phase II TACTI-002 study also designated KEYNOTE-798 with a data cut-off date of 16 April 2021. The data will be presented in two poster presentations by Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, Australia and Dr Irene Brana, Investigator, Vall dHebron Institute of Oncology, Barcelona, Spain at the American Society of Clinical Oncologys ASCO 2021 Annual Meeting in on-demand sessions available from 9 am on 4 June 2021, US Eastern Time at this years virtual conference. The posters will also be made available on Immuteps website from that time at: 